Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

GNX-4728, a novel small molecule drug inhibitor of mitochondrial permeability transition, is therapeutic in a mouse model of amyotrophic lateral sclerosis.

Martin LJ, Fancelli D, Wong M, Niedzwiecki M, Ballarini M, Plyte S, Chang Q.

Front Cell Neurosci. 2014 Dec 19;8:433. doi: 10.3389/fncel.2014.00433. eCollection 2014.

2.

An update on therapeutic opportunities offered by cancer glycolytic metabolism.

Granchi C, Fancelli D, Minutolo F.

Bioorg Med Chem Lett. 2014 Nov 1;24(21):4915-25. doi: 10.1016/j.bmcl.2014.09.041. Epub 2014 Sep 20. Review.

3.

Cinnamic anilides as new mitochondrial permeability transition pore inhibitors endowed with ischemia-reperfusion injury protective effect in vivo.

Fancelli D, Abate A, Amici R, Bernardi P, Ballarini M, Cappa A, Carenzi G, Colombo A, Contursi C, Di Lisa F, Dondio G, Gagliardi S, Milanesi E, Minucci S, Pain G, Pelicci PG, Saccani A, Storto M, Thaler F, Varasi M, Villa M, Plyte S.

J Med Chem. 2014 Jun 26;57(12):5333-47. doi: 10.1021/jm500547c. Epub 2014 Jun 11.

PMID:
24918261
4.

Quantitative chemical proteomics identifies novel targets of the anti-cancer multi-kinase inhibitor E-3810.

Colzani M, Noberini R, Romanenghi M, Colella G, Pasi M, Fancelli D, Varasi M, Minucci S, Bonaldi T.

Mol Cell Proteomics. 2014 Jun;13(6):1495-509. doi: 10.1074/mcp.M113.034173. Epub 2014 Apr 2.

5.

Thieno[3,2-c]pyrazoles: a novel class of Aurora inhibitors with favorable antitumor activity.

Bindi S, Fancelli D, Alli C, Berta D, Bertrand JA, Cameron AD, Cappella P, Carpinelli P, Cervi G, Croci V, D'Anello M, Forte B, Giorgini ML, Marsiglio A, Moll J, Pesenti E, Pittalà V, Pulici M, Riccardi-Sirtori F, Roletto F, Soncini C, Storici P, Varasi M, Volpi D, Zugnoni P, Vianello P.

Bioorg Med Chem. 2010 Oct 1;18(19):7113-20. doi: 10.1016/j.bmc.2010.07.048. Epub 2010 Jul 25.

PMID:
20817473
6.

PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer.

Carpinelli P, Ceruti R, Giorgini ML, Cappella P, Gianellini L, Croci V, Degrassi A, Texido G, Rocchetti M, Vianello P, Rusconi L, Storici P, Zugnoni P, Arrigoni C, Soncini C, Alli C, Patton V, Marsiglio A, Ballinari D, Pesenti E, Fancelli D, Moll J.

Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3158-68.

7.

Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358.

Modugno M, Casale E, Soncini C, Rosettani P, Colombo R, Lupi R, Rusconi L, Fancelli D, Carpinelli P, Cameron AD, Isacchi A, Moll J.

Cancer Res. 2007 Sep 1;67(17):7987-90.

8.

6-Substituted pyrrolo[3,4-c]pyrazoles: an improved class of CDK2 inhibitors.

Brasca MG, Albanese C, Amici R, Ballinari D, Corti L, Croci V, Fancelli D, Fiorentini F, Nesi M, Orsini P, Orzi F, Pastori W, Perrone E, Pesenti E, Pevarello P, Riccardi-Sirtori F, Roletto F, Roussel P, Varasi M, Vulpetti A, Mercurio C.

ChemMedChem. 2007 Jun;2(6):841-52.

PMID:
17450625
9.

1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile.

Fancelli D, Moll J, Varasi M, Bravo R, Artico R, Berta D, Bindi S, Cameron A, Candiani I, Cappella P, Carpinelli P, Croci W, Forte B, Giorgini ML, Klapwijk J, Marsiglio A, Pesenti E, Rocchetti M, Roletto F, Severino D, Soncini C, Storici P, Tonani R, Zugnoni P, Vianello P.

J Med Chem. 2006 Nov 30;49(24):7247-51.

PMID:
17125279
10.

PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity.

Soncini C, Carpinelli P, Gianellini L, Fancelli D, Vianello P, Rusconi L, Storici P, Zugnoni P, Pesenti E, Croci V, Ceruti R, Giorgini ML, Cappella P, Ballinari D, Sola F, Varasi M, Bravo R, Moll J.

Clin Cancer Res. 2006 Jul 1;12(13):4080-9.

11.

3-Amino-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: a new class of CDK2 inhibitors.

Pevarello P, Fancelli D, Vulpetti A, Amici R, Villa M, Pittalà V, Vianello P, Cameron A, Ciomei M, Mercurio C, Bischoff JR, Roletto F, Varasi M, Brasca MG.

Bioorg Med Chem Lett. 2006 Feb 15;16(4):1084-90. Epub 2005 Nov 14.

PMID:
16290148
12.

Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition.

Fancelli D, Berta D, Bindi S, Cameron A, Cappella P, Carpinelli P, Catana C, Forte B, Giordano P, Giorgini ML, Mantegani S, Marsiglio A, Meroni M, Moll J, Pittalà V, Roletto F, Severino D, Soncini C, Storici P, Tonani R, Varasi M, Vulpetti A, Vianello P.

J Med Chem. 2005 Apr 21;48(8):3080-4.

PMID:
15828847
13.

Correction of dyslipoproteinaemia of casein-fed rabbit by FCE 27677, a potent novel ACAT inhibitor.

Chiari A, Lovisolo P, Fogliatto G, Fancelli D, Ghiselli G.

Pharmacol Res. 1996 Mar;33(3):181-9.

PMID:
8880889
14.

FCE 27677: a novel inhibitor of acyl-CoA: cholesterol acyltransferase with potent oral hypolipidemic activity.

Chiari A, Lovisolo P, Radice A, Giorgini L, Fancelli D, Severino D, Ghiselli G.

Pharmacol Res. 1995 Oct;32(4):189-99.

PMID:
8866834
15.

Imidazolylbenzopyrane derivatives: a new class of acyl-CoA: cholesterol acyltransferase (ACAT) inhibitors.

Fancelli D, Chiari A, Cozzi P, Lovisolo P, Severino D, Ghiselli G.

J Enzyme Inhib. 1994;8(3):159-72.

PMID:
7539485

Supplemental Content

Loading ...
Support Center